The KDM5D Knockout KYSE-30 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with disrupted KDM5D in the human esophageal squamous cell carcinoma line KYSE-30. This model facilitates investigation of KDM5D??s role in epithelial-mesenchymal transition (EMT), metastasis, and Y-linked tumor suppression. The polyclonal format provides a heterogeneous loss-of-function pool, avoiding clonal selection biases and enabling robust population-based assays.
KYSE-30 is derived from a well-differentiated esophageal squamous cell carcinoma of a 64-year-old male. This widely used ESCC line retains epithelial characteristics and is appropriate for studying adhesion, migration, and invasion. Its male origin is particularly relevant for analyzing Y-chromosome genes like KDM5D, potentially contributing to sex-based differences in cancer biology.
KDM5D encodes a histone demethylase that removes methyl groups from H3K4me2/me1, functioning as a transcriptional repressor. It directly represses pro-mesenchymal genes including SNAI1 and MMP2 by demethylating their promoters, thereby inhibiting EMT. KDM5D activity is regulated through interactions with the androgen receptor (AR), HDAC1/2, SIN3A, and RB1, and its expression is activated by AR, SOX9, and SP1. Knockout of KDM5D in KYSE-30 cells consequently elevates H3K4 methylation at target loci, upregulating SNAI1, MMP2, and VIM while downregulating CDH1, enhancing invasive capacity.
In KYSE-30 cells, KDM5D acts as a tumor suppressor by restraining EMT and metastatic dissemination. CRISPR-mediated disruption mimics loss-of-function conditions seen in advanced carcinomas, enabling dissection of epigenetic reprogramming that drives invasion. The polyclonal knockout population reflects tumor heterogeneity, offering a more physiologically relevant model than clonal isolates. This system is valuable for exploring male-specific molecular mechanisms in ESCC linked to Y-chromosome-encoded tumor suppressors.
Typical applications include Western blotting and RT-qPCR for EMT markers (SNAI1, CDH1, VIM, MMP2), Transwell migration/invasion, and wound healing assays to assess motility. ChIP-qPCR can map H3K4me2/me1 changes at KDM5D target promoters. RNA-seq enables transcriptome-wide profiling of KDM5D-dependent pathways. These tools support studies in gender-specific tumor biology, epigenetic regulation of metastasis, and identification of anti-metastatic drug targets. For further information, contact Ascent Research.
